Limited experience is available on the feasibility and efficacy of high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL). Therefore, a nation-wide survey was conducted in adult patients transplanted for PTCL in Finland during 1990Finland during -2001. After histopathology review, 37 patients were identified. The median age was 46 years (16-68) at the time of ASCT. Histology included PTCL not otherwise specified in 14 patients, anaplastic large cell lymphoma (ALCL) in 14 patients, and other in nine patients. Disease status at the time of ASCT was CR/PR1 in 18 patients; CR/PR2 in 14 patients, and other in five patients. HDT consisted of either BEAC (N ¼ 22) or BEAM (N ¼ 15), supported by blood stem cells in 34 patients (92%). Early transplantrelated mortality was 11%. With a median follow-up of 24 months from HDT, 16 patients (43%) have relapsed or progressed. The estimated 5-year overall survival (OS) was 54%. Patients with ALCL had superior OS when compared with other subtypes (85 vs 35%, P ¼ 0.007). OS at 5 years was 63% in patients transplanted in CR/PR1 vs 45% in those transplanted in other disease status (P ¼ NS). Prospective studies are needed to define the role of ASCT in this lymphoma type.
cell transplantation; toxicity; outcome About 10% of all non-Hodgkin's lymphomas (NHL) in the Western countries are classified as peripheral T-cell lymphomas (PTCL).
1 T-cell phenotype is associated with poorer prognosis when compared to patients with aggressive B-cell lymphomas. [2] [3] [4] [5] Although PTCL are usually chemosensitive the risk of relapse is high. 6 The International Prognostic Index (IPI) can also be used in patients with PTCL. 7 Depending on the IPI, about 15-35% of the patients become long-term survivors with standard chemotherapy. 8 High-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) might represent a treatment option in patients with PTCL in order to improve the currently dismal prognosis. Unfortunately, experience on HDT in this patient population is limited. Owing to the rarity and heterogeneity of PTCL, prospective randomised trials are difficult to perform. There have been some reports on HDT in patients with anaplastic large cell lymphoma (ALCL) [9] [10] [11] and some retrospective analysis including also other subtypes. [12] [13] [14] [15] [16] To evaluate the feasibility and efficacy of HDT supported by ASCT in adult patients with PTCL, a nation-wide survey including all six transplant centres was undertaken.
Patients and methods

Patients
In 1990-2001, 1188 adult patients received HDT supported by ASCT in six Finnish transplant centres. Altogether 42 patients with the initial diagnosis of PTCL were identified from this cohort. Immunohistochemical studies were available in all cases. After histopathology review by two experienced haematopathologists (KF, K-OS), 37 patients were judged to have PTCL. The histopathological classification was initially based, in the majority of the patients, on the REAL classification, 17 which was later modified to fulfil the requirements of the WHO classification. 1 The characteristics of the patients are presented in Table 1 .
Staging
The Ann Arbor staging was used based on clinical examination, computed tomography and bone marrow aspirate and trephine biopsy. The same methods were used for the evaluation of treatment response to conventional therapy as well as to HDT.
Treatment before stem cell mobilisation
All patients except one had received anthracycline-based chemotherapy before the inclusion into HDT protocols. The median number of chemotherapy courses was 7 (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The median number of chemotherapy regimens before the progenitor cell mobilisation was 2 (1-4). Seven patients (19%) had received local radiotherapy.
Mobilisation of progenitor cells
Progenitor cell mobilisation was attempted in 35 patients. The most common regimen was cyclophosphamide (usually 4 g/m 2 ) plus G-CSF (20 patients). A total of 13 patients received disease-specific chemotherapy plus G-CSF. Two patients were mobilised with growth factors alone. Two patients who entered HDT protocol in the early 1990 s went on directly to marrow harvest.
HDT protocols
The condition regimens consisted either of BEAC (N ¼ 22) or BEAM (N ¼ 15). In all, 34 patients (92%) received blood stem cell grafts and three marrow grafts. G-CSF was started after the progenitor cell infusion in 34 patients (92%). Six patients (16%) received local radiotherapy after HDT either due to previous bulky tumour or due to a residual tumour.
Response criteria
Complete remission (CR) was defined as disappearance of all clinical and radiographic evidence of lymphoma. Partial remission (PR) was defined as at least 50% reduction in tumour mass as assessed with clinical examination, computed tomography or trephine biopsy.
Statistical methods
The data were analysed with SPSS 9.0 for Windows (SPSS Incorporation, Chicago, IL, USA). Overall survival (OS) and progression-free survival (PFS) were analysed from the date of transplantation by the product-sum method of Kaplan-Meier. 18 The differences in survival times between the groups were compared with the log-rank test. MannWhitney's nonparametric U-test was used to assess the differences in continuous variables between the groups. The w 2 test was used for the analysis of the nominal data. Pvalues o0.05 were considered statistically significant. Higher P-values are denoted as NS (not significant).
Results
Stem cell mobilisation and apheresis
The median peak blood CD34 þ count measured after the mobilisation was 44 Â 10 6 /1 (6-285). With a median of two aphereses (1-5), a median of 4.1 Â 10 6 /kg CD34 þ cells (0.16-25.0) was collected. In six patients (16%), the minimum collection target (2 Â 10 6 /kg CD34 þ cells) was not reached. In three patients grafts containing 1.3-1.7 Â 10 6 /kg CD34 þ cells were considered sufficient to proceed to HDT. Two patients were remobilised with G-CSF and VIG (etoposide, ifosfamide and G-CSF) and grafts containing 1.0 and 1.5 Â 10 6 /kg CD34 þ cells were collected, respectively. One patient who failed to mobilise went on to marrow harvest.
The median number of aphereses was comparable in patients mobilised with either cyclophosphamide or with disease-specific chemotherapy (2 vs 2). Also, the median number of CD34 þ cells collected was comparable between the groups (3.9 vs 4.1 Â 10 6 /kg). The proportion of patients failing to mobilise at least 2 Â 10 6 /kg CD34 þ cells was 10% among patients mobilised with cyclophosphamide plus G-CSF and 23% in patients mobilised with disease-specific chemotherapy plus G-CSF (P ¼ NS).
Toxicity of HDT
Neutropenic fever (4381C) was observed in 36 patients (97%). Blood cultures were positive in 13 patients (35%). The culture findings included Staphylococcus epidermidis
Four patients died from transplant-related reasons o100 days from ASCT giving an early transplant-related mortality (TRM) of 11%. Data on these patients are summarised in Table 2 . TRM was 20% in patients who received BEAM vs 5% in those treated with BEAC (P ¼ NS). One patient died at 4 months in remission with signs of viral pneumonia and vasculitis and another at 15 months in remission due to cardiomyopathy (not present before HDT). Thus the TRM of the whole series was 16%. In addition to these patients, three patients experienced a WHO grade 42 toxicity (excluding mucositis and diarrhoea). One patient developed a septic shock, which could be managed without intensive care, another needed temporary ventilatory assistance and one patient received prolonged parenteral nutrition.
Engraftment
Two patients were not evaluable for engraftment due to early death (day 0 and day þ 8). All other patients engrafted. The median times to reach neutrophils 40.5 Â 10 9 /1 and unsupported platelets 420 Â 10 9 /1 were 10 days (8-17) and 11 days (8-not reached), respectively.
Response and survival after HDT
Four patients (11%) were not evaluable for response to HDT due to early death. Altogether 28 patients (76%) achieved or maintained a CR. Two patients (5%) achieved a PR, but progressed at 1 and 4 months, respectively. Three patients (8%) were refractory to HDT and died from progressive lymphoma.
The projected 5-year OS for the whole patient group was 54% (Figure 1) . OS was significantly better in patients with ALCL compared to patients with other subtypes (85 vs 35%, P ¼ 0.007) (Figure 2 ). These patient groups were comparable on the basis of pretransplant characteristics ( Table 3 ). The 5-year OS was 63% in patients transplanted in CR/PR1 vs 45% in patients transplanted later (P ¼ NS). In regard to patient characteristics, IPI at diagnosis was significantly higher in patients transplanted in CR/PR1 (3 vs 1, Po0.001) ( Table 4 ). The OS was comparable in patients conditioned either with BEAC or BEAM.
With a median follow-up of 24 months (0-139) from HDT, 16 patients (43%) have progressed or relapsed. The median time to relapse or progression was 8 months (0-52). Table 2 Characteristics of four patients with PTCL who experienced an early TRM (o100 days from ASCT) 
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The projected 5-year PFS was 44% for the whole patient cohort (Figure 3 ). PFS was superior in patients with ALCL when compared to other patients, but the difference did not reach statistical significance (Figure 4 ). Only one of the 11 patients transplanted for systemic ALCL relapsed whereas all three patients with cutaneous ALCL relapsed. PFS was 64% in patients transplanted in CR/PR1 vs 28% in patients who received HDT later (P ¼ NS). No difference was observed in PFS between patients conditioned with either BEAC or BEAM.
Outcome of patients with relapse or progression after HDT
Of the 16 patients who relapsed or progressed after HDT, 11 patients received therapy for lymphoma. Six patients (54%) achieved CR, two patients PR and two patients did not respond. One patient was not evaluable for response due to toxic death. A patient who achieved CR went on to unrelated allogeneic SCT, but died from lymphoma and complications of the transplantation. To date, nine patients have died from progressive lymphoma. Six relapsed patients are currently alive 7-92 þ months from the relapse. Four patients (25%) have survived for at least 24 months. Two of these patients had initially cutaneous form of ALCL, one patient had systemic ALCL and one patient PTCL NOS. The median survival following relapse or progression after HDT was 7 months.
Discussion
The present analysis is the first nation-wide study on HDT supported by ASCT in patients with PTCL. This series, although retrospective, gives some estimates on the feasibility and efficacy of HDT in this patient population where randomised studies are hard to perform due to the rarity of the disease. The major findings were better outcome of patients with ALCL, reasonable prognosis in patients who received ASCT after a relapse and relatively high TRM especially in patients conditioned with BEAM. These findings may be of importance in planning future studies of HDT in patients with PTCL.
Although the concept of poorer prognosis of PTCL when compared with the most B-cell lymphoma subtypes has been generally accepted, limited progress has been achieved in the treatment of these lymphomas until recently. In most cases, patients with PTCL have been treated with regimens developed and validated in the more common B-cell lymphomas. Yet, there may be biological differences between T-cell and B-cell lymphomas, which may have Table 3 Comparison of patients with ALCL and non-ALCL PTCL Table 4 Comparison of patient characteristics of patients transplanted in CR/PR1 vs 4CR/PR1 ASCT in peripheral T-cell lymphomas E Jantunen et al therapeutic implications. Although PTCL are usually chemosensitive initially, the risk of relapse is high. Therefore, consolidation with HDT has been suggested. 5 Scanty information is available on the feasibility, toxicity and efficacy of HDT with ASCT in patients with PTCL in general and specifically in many subtypes defined in the most recent lymphoma classifications. 1, 17 No published data are available on the mobilisation of progenitor cells in patients with PTCL. According to this analysis, the target CD34 þ collection was achieved in 84% of the patients. This is similar to the figure observed in a single centre experience of progenitor cell mobilisation in 120 patients with NHL of various histologies. 19 No conclusion can be drawn on the relative merits of cyclophosphamide vs disease-specific mobilisation therapy on the basis of our analysis. The disease status of the patients and local preferences and experiences are obviously important in the decision-making in regard to optimal mobilisation regimen.
Toxicity associated with HDT was considerable in this series. The early TRM has been below 10% in previous analyses of patients with PTCL. 13, 14, 20 Our figure for the early TRM (11%) may be considered high in the era of blood progenitor cell support. Especially patients with EATL may have higher risks (TRM 40% in this small series) perhaps due to disease characteristics and more data is needed on the feasibility of ASCT in this subtype. If patients with EATL are excluded, the early TRM is 6% in this series. For comparison, retrospective analyses from the same transplant centres have shown an early TRM of 5% in patients with mantle cell lymphoma 21 and 3.5% among patients with follicular lymphoma (unpublished).
Limited data is available on the relative toxicity of various high-dose regimens commonly used in patients with NHL. A retrospective single centre analysis suggested that BEAM might be more toxic than BEAC, although no differences in OS or PFS were observed. 22 The present study suggests that TRM may be higher in PTCL patients conditioned with BEAM, although OS and PFS were comparable with the patients conditioned with BEAC. Owing to small patient numbers and retrospective nature of analysis, this issue deserves further studies.
Patients with ALCL fared better after HDT than patients with other subtypes of PTCL. This is in line with previous observations. 13, 16 In fact, a very low relapse rate after ASCT has been observed in a retrospective analysis of EBMT. 10 In our series, only one patient (9%) with systemic ALCL relapsed during the observation period, whereas all patients with primary cutaneous ALCL relapsed. ALCL has perhaps better prognosis than any other NHL subtype with anthracycline-based chemotherapy. 8 Considering the potential risks of HDT and the promising results of conventional chemotherapy, 23 HDT with ASCT might not be indicated in the first remission in patients with ALCL if there are no bad prognostic features. Alk expression has been associated with a better prognosis in patients with systemic ALCL, [24] [25] [26] [27] and might thus be a useful adjunct in the risk assessment of the patients with systemic ALCL. During the study period of the present analysis, alk staining was not at wide use and was not used for clinical decision-making.
This analysis as well as some other reports 13, 14, 16 suggest that HDT with ASCT is an effective therapy in relapsed PTCL patients. PFS seems to be of the same order as in relapsed aggressive B-cell lymphomas. However, a high relapse rate is still observed in these patients suggesting that at least in some patients other treatment should be considered. Conventional allogeneic stem cell transplantation or ASCT followed by nonmyeloablative allogeneic transplant might be worth considering in some high-risk patients.
As with most other subtypes of NHL, [28] [29] [30] the prognosis of PTCL patients who relapse or progress after ASCT is rather poor. In patients with an early relapse or progression, practically no effective therapy is at present available. In addition to the refractoriness to chemotherapy, the general condition of the patients does not usually allow intensive therapeutic approaches. However, in patients who relapse later after HDT, the situation is more favourable. A significant proportion of our patients responded to therapy and 25% of the patients became long-term survivors. These patients may benefit from some type of allogeneic approach to prevent further relapses.
To conclude, this nation-wide analysis suggests that ASCT is feasible in patients with PTCL although TRM seems to be relatively high. Prospective studies are necessary in order to define more precisely the role of HDT in these rare lymphomas. Preferably these studies should be randomised between chemotherapy and chemotherapy plus ASCT in early disease.
